At the National Kidney Foundation (NKF) 2026 conference, a professional standoff between experienced nephrologists was dedicated to a critical medical dilemma: the management tactics for chronic hyponatremia. Specialists debated whether sodium levels must be corrected strictly slowly to prevent Osmotic Demyelination Syndrome (ODS), or if a faster pace is permissible in certain patients.
Why is Hyponatremia Dangerous?
Sodium is an essential electrolyte that ensures the proper functioning of cellular structures, particularly neurons. A sharp drop in sodium levels leads to dangerous hyperhydration and swelling of brain tissues. The clinical presentation includes nausea, headache, altered consciousness, seizures, and in severe cases, fatal outcomes.
This pathology is far more common than one might imagine. Risk groups include hospitalized patients, the geriatric population, marathon runners (due to overhydration), as well as individuals with liver cirrhosis, heart failure, or those on specific medication therapies.
When this electrolyte imbalance develops gradually over days or weeks, it is classified as chronic hyponatremia, during which the nervous system adapts to the new levels. It is precisely this compensatory adaptation that significantly complicates the treatment process.
The Risks of Rapid Correction
The primary dilemma facing clinicians is linked to this adaptive mechanism. For a brain that has grown accustomed to low sodium levels, a forced, rapid restoration of sodium is a devastating blow. This imbalance can trigger a severe pathology—Osmotic Demyelination Syndrome (ODS)—which involves the destruction of the myelin sheath protecting nerve fibers. ODS often manifests as paralysis, dysphagia (difficulty swallowing), irreversible neurological deficits, and death.
To avoid this fatal complication, current medical guidelines mandate only gradual electrolyte restoration. Specifically, in high-risk groups, the rate of sodium increase should not exceed 8 mmol/L per day, while in average-risk individuals, the limit is 10-12 mmol/L. These clinical restrictions have been an unshakable standard in medical practice for decades. However, modern medical evidence suggests a need to re-evaluate these constraints.
Arguments for Rapid Correction
According to Dr. Juan Carlos Velez, Professor of Nephrology at Ochsner Health, the fear of developing ODS in clinical practice is clearly exaggerated, while the negative consequences of prolonged hyponatremia are consistently underestimated.
His primary thesis is based on several points:
The Role of Specific Risk Factors: The development of ODS is extremely rare unless the patient meets strictly defined high-risk criteria. These anamestic factors include alcoholism, cachexia, extremely low baseline sodium levels, hypokalemia, and severe liver disease. Without these criteria, rapid therapy is considered a safe therapeutic method.
Statistical Evidence: In a large-scale 2023 study involving 23,000 patients admitted with hyponatremia across five leading Canadian hospitals, rapid correction was utilized in 18% of cases. Despite this, ODS occurred in only 0.05% of the total population. Another recent analysis (based on data from 14,000 patients) showed that active therapy significantly reduces neurological complications and mortality over a 90-day period.
Practical Difficulties of Treatment: The speaker highlighted the technical difficulty of slow correction. Despite maximum control by medical staff, patients still exceed the target speed in 28-69% of cases. Sodium dynamics respond directly to the body’s endogenous, unpredictable responses. Consequently, holding clinicians legally liable for unmanageable biological processes is scientifically unjustified.
Dr. Velez concluded that current guidelines instill excessive caution in the medical community. This approach leads to inadequate treatment and the underutilization of highly effective medications like vaptans. Therefore, existing clinical protocols should be revised.
Arguments for Slow Correction
Dr. Helbert Rondon-Berrios, Professor of Medicine at the University of Pittsburgh, presented the opposing position with a careful and methodical approach.
In his critique of the opposition, he focused on several fundamental factors:
Selection Bias: Berrios explained that the low incidence of ODS is caused by methodological flaws in studies claiming that rapid correction is safe. For example, in the Canadian study cited by Velez, 90% of patients had baseline sodium levels above 120 mmol/L. This is a moderate degree of hyponatremia where daily limits (8 mmol/L) are generally not triggered anyway. However, when the professor evaluated the severe cohort (≤110 mmol/L) separately, the ODS rate rose to 2.6%—50 times higher than the overall average.
Diagnostic Imperfections: Identifying ODS is practically impossible without active searching. Confirming the pathology requires Magnetic Resonance Imaging (MRI), which was not performed on all patients in the cited studies. Berrios pointed to a stark discrepancy: while the Canadian group recorded only 7 cases of ODS in their database, neurologists at the same clinic, during the same period, discovered 45 cases through targeted research.
Misinterpretation of Causes: The professor questioned the evidence that rapid rates reduce mortality. In studies where slow correction showed higher lethality, the patients were much more severely ill at baseline (with liver cirrhosis, terminal oncology, and heart failure). In these cases, sodium levels failed to rise not because of cautious therapy, but because of the severity of the primary disease. Therefore, comparing these groups is not scientifically sound.
Internal Clinical Data: His ongoing research, which includes extremely severe patients (≤105 mmol/L), showed a sobering picture. Among those where the correction speed exceeded 8 mmol/L per day, the rate of ODS development was 22%. Under slow-pace conditions, this complication was not recorded at all.
In Berrios’s view, existing guidelines are entirely valid and rational, especially for high-risk populations. Studies advocating for a more liberal approach contain serious methodological flaws that cannot be ignored.
The Search for Consensus
In reality, both nephrologists agree on far more than it might appear at first glance. The primary discussion concerns tactical boundaries and the validity of new scientific evidence that challenges long-standing standards.
The situation is further complicated by the fact that conducting precise scientific experiments in this field is very difficult. Sodium changes are affected not only by infusions but also by the body’s unique biochemical processes. Furthermore, “blinding” doctors and patients from the treatment method is physically impossible, and ODS itself is so rare that studying it requires data from millions of people.
While scientists debate, doctors in hospitals must make decisions every minute. A nephrologist facing a severely ill patient assesses the benefits of treatment against potential risks every time.
Currently, the medical community is leaning toward a more balanced, compromise-based approach: high-risk individuals (extreme hyponatremia, alcoholism, malnutrition, cirrhosis) are still managed with the traditional slow method, while in relatively milder cases, doctors are given more freedom of action. This is not an ideal solution, but absolute answers in medicine are rare.
Source: Medscape
